Page last updated: 2024-11-07

2-acetylcyclopentanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Acetylcyclopentanone is a cyclic β-diketone. It is a colorless liquid with a strong odor. 2-Acetylcyclopentanone is synthesized by the reaction of cyclopentanone with acetic anhydride in the presence of a base catalyst. It is used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. 2-Acetylcyclopentanone is also studied for its potential biological activity. For example, it has been shown to inhibit the growth of certain cancer cells. It is a versatile building block in organic synthesis, and its reactivity is attributed to the presence of the two carbonyl groups, which are in close proximity. The α-methylene group between the carbonyl groups is particularly reactive and can be easily deprotonated, making it a useful substrate for a variety of reactions. Its importance lies in its use as an intermediate in the synthesis of a variety of useful compounds, including pharmaceuticals, agrochemicals, and other organic materials. Researchers study it for its potential biological activity and its reactivity in organic synthesis.'

2-acetylcyclopentanone: an enolate-forming compound that is protective against electrophilic drugs; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID98471
CHEMBL ID305069
SCHEMBL ID535830
MeSH IDM0587949

Synonyms (33)

Synonym
2-acetyl cyclopentanone
cyclopentanone, 2-acetyl-
1670-46-8
nsc-141181
.alpha.-acetylcyclopentanone
2-acetylcyclopentanone
nsc141181
2-acetylcyclopentan-1-one
nsc 141181
ai3-19254
einecs 216-797-5
o-acetylcyclopentanone
brn 1857601
alpha-acetylcyclopentanone
acetylcyclopentanone
2-acetylcyclopentanone, 98%
A0869
CHEMBL305069
STK801991
A810811
AKOS005207311
4-07-00-01993 (beilstein handbook reference)
FT-0610975
SCHEMBL535830
2-acetyl-cyclopentanone
mfcd00001413
F0001-0610
J-010333
DTXSID90862730
F17111
EN300-173318
CS-W011158
SY048589
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1893771Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID74488Inhibitory activity against murine gelatinase B at 5 mM was determined2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Design and synthesis of novel inhibitors of gelatinase B.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.76 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]